Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.64 |
| ▸ | CNR1 | P21554 | 7/20 | 0.64 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 4/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4341823 | 0.87 | CNR1 (0.54) | CNR2CNR1NAMPTUSP2LMNA | |
| SCHEMBL4341825 | 0.87 | CNR1 (0.63) | CNR2CNR1NAMPTUSP2LMNA | |
| SCHEMBL4340056 | 0.84 | CNR2 (0.68) | CNR2CNR1FAAH | |
| SCHEMBL4330441 | 0.83 | CNR2 (0.61) | CNR2CNR1 | |
| SCHEMBL4324493 | 0.83 | CNR2 (0.74) | CNR2CNR1FAAHADORA2AADORA1 | |
| SCHEMBL4326414 | 0.82 | CNR2 (0.68) | CNR2CNR1NAMPTFAAH | |
| SCHEMBL4321720 | 0.82 | CNR2 (0.70) | CNR2CNR1USP2 | |
| SCHEMBL4334559 | 0.81 | CNR2 (0.62) | CNR2CNR1SMN1; SMN2 | |
| SCHEMBL4341751 | 0.81 | CNR2 (0.64) | CNR2CNR1FAAH | |
| SCHEMBL4468815 | 0.81 | CNR2 (0.69) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885NAMPT 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.